

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BOULAY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/014549

FILED: 21 DECEMBER 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES  
TO MTOR INHIBITORS**MS: Amendment**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/014549, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7909  
Date: June 19, 2006  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

33564-US-PC

APPLICATION NO.

Not Yet Known

APPLICANT

BOUDAY ET AL

FILING DATE

Herewith

APR 10 2006 PCT/PTO 19 JUN 2006

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/46471	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/020582	3/11/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	03/034067	4/24/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Neshat et al., "Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR", Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 18, pp. 10314-10319 (2001).
AS	Hidalgo et al, "The Rapamycin-Sensitive Signal Transduction Pathway as a Target for Cancer Therapy", Oncogene, Vol. 19, No. 56, pp. 6680-6686 (2000) -- Abstract.
AT	Kwiatkowski et al., "A Mouse Model of TSC1 Reveals Sex-Dependent Lethality from Liver Hemangiomas, and Up-Regulation of p70S6 Kinase Activity in Tsc1 Null Cells", Human Molecular Genetics, Vol. 11, No. 5, pp. 525-534 (2002) -- Abstract.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33564-US-PCT  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
BOULAY ET AL.  
FILING DATE  
Herewith10/583674  
IAP20060617PTO 19 JUN 2006  
GroupEXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BA	Shi et al., "Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779", Cancer Research, Vol. 62, No. 17, pp. 5027-5034 (pp. 2002).
BB	Huang et al., "Resistance to Rapamycin: A Novel Anticancer Drug", Cancer and Metastasis Reviews, Vol. 20, No. 1-2, pp. 69-78 -- Abstract.
BC	Fukazawa et al., "Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated...", Molecular Cancer Therapeutics, Vol. 1, No. 5, pp. 303-309 (2002) -- Abstract.
BD	Dumont et al., "Mechanism of Action of the Immunosuppressant Rapamycin", Life Sciences, Vol. 58, No. 5, pp. 373-395 -- Abstract.
BE	
BF	
BG	
BH	
BI	
BJ	
BK	
BL	
BM	
BN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.